{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination broadens tumor antigen display, increasing the represented proteins in both the immunopeptidome and the MHC-I peptidome.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "| Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |",
          "line_ref": "L28"
        },
        {
          "quote": "| Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |",
          "line_ref": "L29"
        },
        {
          "quote": "A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.",
          "line_ref": "L44"
        }
      ],
      "caveat": "These summary values do not specify tumor-model variability, and some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings."
    },
    {
      "claim_id": "C02",
      "claim": "Intratumoral mRNA vaccination induces a type I interferon response in tumors, and type I interferon signaling is required for the sensitization benefit.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
          "line_ref": "L42"
        },
        {
          "quote": "| Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |",
          "line_ref": "L31"
        },
        {
          "quote": "- Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
          "line_ref": "L39"
        }
      ],
      "caveat": "The report summarizes the mechanism at a high level; mouse model effects may not map one-to-one to all human tumors."
    },
    {
      "claim_id": "C03",
      "claim": "mRNA vaccination increases PD-L1 pathway activity in tumor tissue, providing a rationale for combining intratumoral vaccination with anti-PD-L1 checkpoint blockade.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "| PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable |",
          "line_ref": "L32"
        },
        {
          "quote": "PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.",
          "line_ref": "L45"
        }
      ],
      "caveat": "An increase in PD-L1 expression does not by itself guarantee clinical benefit, and translation from mouse tumor settings to diverse human tumors is uncertain."
    },
    {
      "claim_id": "C04",
      "claim": "Combination treatment with intratumoral mRNA vaccination and anti-PD-L1 is associated with increased intratumoral CD8+ T-cell density and improved tumor control in mice.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "- Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.",
          "line_ref": "L14"
        },
        {
          "quote": "| Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy |",
          "line_ref": "L33"
        },
        {
          "quote": "Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
          "line_ref": "L46"
        }
      ],
      "caveat": "The magnitude and consistency of these effects may vary by model system, and mouse model effects may not map one-to-one to all human tumors."
    },
    {
      "claim_id": "C05",
      "claim": "In a retrospective metastatic patient cohort treated with immune checkpoint inhibitors, prior SARS-CoV-2 mRNA vaccination status was associated with improved survival.",
      "strength": "tentative",
      "evidence": [
        {
          "quote": "- Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.",
          "line_ref": "L15"
        },
        {
          "quote": "| Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |",
          "line_ref": "L30"
        },
        {
          "quote": "- The human analysis is retrospective and non-randomized; residual confounding is likely.",
          "line_ref": "L49"
        }
      ],
      "caveat": "Because the human analysis is retrospective and non-randomized with variable vaccination timing and heterogeneous tumor types, the observed association cannot be interpreted as definitive causation."
    }
  ]
}